Navigation Links
Uroplasty Reports Fiscal First Quarter 2014 Financial Results

MINNEAPOLIS, Aug. 1, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2014 first quarter ended June 30, 2013. 

Fiscal First Quarter 2014 Financial ResultsFiscal first quarter 2014 sales in the U.S. increased 6%, driven by a 10% increase in sales of the Urgent® PC Neuromodulation System, compared with fiscal first quarter a year ago.  U.S. Urgent PC Sales in the fiscal first quarter of 2014 were $2.8 million.  Global sales increased 5% to $5.8 million in the first quarter of fiscal 2014, compared with $5.6 million in the fiscal first quarter a year ago.

"Fiscal first quarter sales of Urgent PC grew 11% from the fourth quarter of fiscal 2013, despite the distractions we faced.  This was the first sequential quarterly growth we've achieved in three quarters and is a strong indication that the changes we have made in the sales organization are beginning to gain traction," said Rob Kill, President and Chief Executive Officer of Uroplasty. "As we look ahead into the new fiscal year, we are optimistic about the outlook.  We have innovative and effective product lines combined with favorable reimbursement that continues to improve.  The market is large and remains underpenetrated. With the resolution of our leadership and fiscal 2013 financial statements, we are fully focused on growing sales and driving to profitability as we seek to enhance value for our investors."

Net sales to customers outside the U.S. for the fiscal first quarter totaled $1.6 million, compared to $1.5 million in the fiscal first quarter last year.  Excluding the impact of fluctuations in foreign currency exchange rates, sales outside the U.S. were down 3%. 

The Company reported a gross margin of 87.2% in the recent fiscal first quarter compared with 86.5% in the same quarter a year ago.  The operating loss of $1.6 million in the fiscal first quarter compares with a $1.0 million operating loss in the same quarter last year. Excluding non-cash charges for share-based compensation and depreciation and amortization expense, the non-GAAP operating loss was $1.5 million in the first quarter of fiscal 2014, compared with a $567,000 non-GAAP operating loss in the first quarter a year ago.  The increase in operating loss was primarily attributable to an increase in operating expenses.

Novitas Solutions, Inc. Expands Coverage of PTNSUroplasty also announced that, effective today, August 1, 2013, Novitas Solutions, Inc. has expanded coverage for Posterior Tibial Nerve Stimulation (PTNS) using Urgent PC for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.  This increased coverage includes additional diagnostic codes as well as expansion of on-going therapy from 12 months to up to two years.

Novitas Solutions, Inc., a Medicare Administrative Contractor,  provides medical and drug benefits to approximately  11 million Medicare beneficiaries in the states of Arkansas, Colorado, Delaware, District of Columbia, Louisiana, Maryland, Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania and Texas. Novitas has expanded patient access to PTNS by adding diagnosis codes that include frequency, urgency and urge incontinence, the hallmark symptoms of overactive bladder. Uroplasty estimates that PTNS coverage today has been extended to a total of approximately 140 million private coverage and Medicare beneficiaries.

Conference CallUroplasty will host a conference call and webcast today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the fiscal first quarter of 2014.  Rob Kill, President and Chief Executive Officer, will host. Individuals wishing to participate in the conference call should dial 877-941-2333.  No passcode is necessary. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4632547#.

To access a live webcast of the call, go to Uroplasty's website at and click on the Investor Relations section. An archived webcast will also be available at

About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at

Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

For Further Information:
Uroplasty, Inc.
Rob Kill, President and CEO

EVC Group
Jenifer Kirtland (Investors)
Chris Gale (Media)



 UROPLASTY, INC. AND SUBSIDIARIESCONDENSED Consolidated Statements of Operations(Unaudited)Three Months EndedJune 30,20132012Net sales

$5,840,841$5,577,123Cost of goods sold 

748,047755,587Gross profit

5,092,7944,821,536Operating expensesGeneral and administrative

1,580,7631,091,846Research and development

479,660563,041Selling and marketing


6,648215,6096,694,4805,835,331Operating loss

(1,601,686)(1,013,795)Other income (expense)Interest income

9,26412,578Foreign currency exchange (loss) gain

(2,695)(9,671)6,5692,907Loss before income taxes

(1,595,117)(1,010,888)Income tax expense 

14,1758,467Net loss

$(1,609,292)$(1,019,355)Basic and diluted loss per common share

$(0.08)$(0.05)Weighted average common shares outstanding:Basic and diluted




UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)June 30, 2013March 31, 2013AssetsCurrent assets:Cash and cash equivalents & short-term investments

$13,659,835$11,470,469Accounts receivable, net



544,017566,536Total current assets

17,385,27515,309,385Property, plant, and equipment, net

1,151,2181,033,085Intangible assets, net 

93,855100,502Long-term investments

399,6723,451,711Deferred tax assets

145,930146,052Total assets

$19,175,950$20,040,735Liabilities and Shareholders' EquityCurrent liabilities:Accounts payable

$883,827$618,916Current portion – deferred rent

30,87835,000Income tax payable

1627,729Accrued liabilities:Compensation


868,938476,287Total current liabilities

3,355,8332,688,778Deferred rent – less current portion

05,141Accrued pension liability

709,993660,580Total liabilities

4,065,8263,354,499Total shareholders' equity

15,110,12416,686,236Total liabilities and shareholders' equity




UROPLASTY, INC. AND SUBSIDIARIESCONDENSED Consolidated Statements of Cash Flows (Unaudited)Three Months EndedJune 3020132012Cash flows from operating activities:Net loss

$   (1,609,292)$  (1,019,355)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

87,013288,548Loss on disposal of  equipment

(5,881)599Amortization of premium on marketable securities

3,3428,091Share-based consulting expense

01,623Share-based compensation expense

16,044162,435Deferred income tax expense (benefit)

2,178(1,117)Deferred rent credit

(9,263)(9,111)Changes in operating assets and liabilities:Accounts receivable, net


39,773(122,672)Other current assets

23,110(107,267)Accounts payable

264,500137,599Accrued compensation

19,415(202,540)Accrued liabilities

383,43696,108Accrued pension liability, net 

40,07341,029Net cash used in operating activities

(685,094)(701,701)Cash flows from investing activities:Proceeds from maturity of available-for-sale investments

1,000,000-Proceeds from maturity of held-to-maturity investments

820,0003,320,000Purchases of available-for-sale investments

-(3,218,286)Purchases of property, plant and equipment

(189,789)(73,902)Proceeds from sale of property, plant and equipment

6,080-Purchases of intangible assets

-(4,440)Net cash provided by investing activities

1,636,29123,372Cash flows from financing activities:Net cash provided by financing activities

--Effect of exchange rate changes on cash and cash equivalents

9,312(18,642)Net decrease in cash and cash equivalents

960,509(696,971)Cash and cash equivalents at beginning of period

3,533,8644,653,226Cash and cash equivalents at end of period

$4,494,373$3,956,255Cash paid during the period for income taxes


Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these Non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended June 30, 2013 and 2012 was approximately $1.5 million and $561,000, respectively.  The increase in non-GAAP operating loss for the three months ended June 30, 2013 over the corresponding period a year ago is attributed to the increase in operating spending, offset slightly by the increase in net sales and gross profit percent.

 Expense AdjustmentsThree-Months EndedGAAPShare-based  ExpenseDepreciationAmortization of IntangiblesNon-GAAP30-Jun-13Gross Profit





$5,110,000% of net sales

87.2%87.5%Operating ExpensesGeneral and administrative





1,609,000Research and development





465,000Selling and marketing














6,609,000Operating Loss





$(1,499,000)30-Jun-12Gross Profit





$4,837,000% of net sales

86.5%86.7%Operating ExpensesGeneral and administrative





959,000Research and development





550,000Selling and marketing














5,398,000Operating Loss






SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
2. Uroplasty Announces Product Development and New Clinical Trial Initiatives
3. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
4. Uroplasty To Present At The JMP Securities Healthcare Conference
5. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
6. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
7. Uroplasty To Participate In Two Upcoming Conferences
8. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
9. Uroplasty To Participate In Two Upcoming Investor Conferences
10. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
11. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Post Your Comments:
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):